NetworkNewsBreaks Archive - Page 1919 of 1949

FridayDec 16, 2016 2:09 pm

NetworkNewsBreaks – GainClients (GCLT) Exclusive HomeSearch Platform Delivers Custom Results to Consumers

Potential home owners generally know what they want in a new home and don’t want to waste time looking at houses that don’t meet their needs. With the new HomeSearch platform from GainClients, homebuyers can save time and energy by essentially eliminating homes that don’t fit their search criteria. “With this growing demand and a consistently smaller inventory, finding the right home will become more difficult than ever. GainClients, Inc. (OTC: GCLT), a leading provider of technology solutions for the real estate industry, aims at helping consumers look for and identify the right home for them via a comprehensive yet…

ThursdayDec 15, 2016 3:23 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on December 15, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: ESEA 91.37% – News: Acquires feeder containership; announces private placement of common stock LKAI 54.70% – News: Surface drilling program underway at permitted site on LKA’s Golden Wonder Mine IVDA 33.33% – News: Obtained three contracts for safe city projects in Taiwan valued at U.S. $2.6M DRYS 30.14%– News: Refinancing majority of its outstanding debt BOSC 15.07% – News: Supply Chain division receives order of $1.6M OESX 9.18% – News: CEO interviewed on SNNLive…

ThursdayDec 15, 2016 1:25 pm

NetworkNewsBreaks – Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) Resolves Patent Litigation Regarding Schizophrenia Treatment

Vanda Pharmaceuticals (NASDAQ: VNDA) recently resolved its patent litigation against Apotex regarding Apotex's Abbreviated New Drug Application seeking approval of its generic version of Vanda's Fanapt® (iloperidone). Under a licensing agreement, Vanda has granted Apotex a non-exclusive license to manufacture and commercialize its version of Fanapt® in the U.S., effective November 2, 2027. Fanapt® in 2009 was approved by the FDA for the treatment of schizophrenia in adults. In 2012, the drug was approved for marketing in Israel and Argentina. To view the full press release, visit: http://nnw.fm/XSt0U About Vanda Pharmaceuticals Inc. Vanda is a specialty pharmaceutical company focused on…

ThursdayDec 15, 2016 1:21 pm

NetworkNewsBreaks – Ocera Therapeutics, Inc. (NASDAQ: OCRX) Targets Hepatic Encephalopathy, a Complication of Liver Cirrhosis, with OCR-002

Ocera Therapeutics (NASDAQ: OCRX) is focused on the development of OCR-002 (ornithine phenylacetate) to treat hyperammonemia and subsequent hepatic encephalopathy (HE). An estimated eight million people in the U.S. suffer from chronic liver disease and approximately one million suffer from liver cirrhosis. HE is a debilitating and progressive complication of liver cirrhosis or liver failure marked by mental changes including confusion, impaired motor skills, and disorientation. Severe HE can cause stupor, coma and even death. Currently, there are no drug treatments that can be given intravenously to hospitalized patients with acute HE. To learn more visit www.ocerainc.com About Ocera Ocera…

ThursdayDec 15, 2016 1:18 pm

NetworkNewsBreaks – CytoDyn Inc. (CYDY) Advances Clinical Trials for PRO 140 for HIV Infection

Cytodyn (OTCQB: CYDY) is focused on enhancing the lives of people with infectious diseases through the development of new antibody treatments to battle human immunodeficiency virus (HIV) infection. An estimated 1.2 million people in the United States were living with HIV at the end of 2013, the most recent year for which this information is available. Cytodyn recently reported the first several patients have been treated in its phase 3 clinical trial with PRO 140, its proprietary drug that can significantly reduce viral burden in people infected with HIV. PRO 140 works by blocking the HIV co-receptor CCR5 on T-cells…

ThursdayDec 15, 2016 1:16 pm

NetworkNewsBreaks – Medical Transcription Billing, Corp. (NASDAQ: MTBC) Shows Promise as the Dark Horse of RCM Market

Medical Transcription Billing, Corp. (NASDAQ: MTBC) (NASDAQ: MTBCP) is one of many progressive firms vying to enter the U.S. ambulatory EHR/RCM (revenue cycle management) market, which is valued at more than $13 billion. “Currently, there are at least 1,500 companies offering RCM services in this highly competitive arena. None commands more than 10 percent of market share. The largest, athenahealth (NASDAQ: ATHN), has about 7% of the market. With annual revenues that are likely to exceed $1.0 billion this year, the market value of its equity is close to 4x revenues. Its stock currently trades at around $93.00. This makes…

WednesdayDec 14, 2016 2:47 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on December 14, 2016

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: BLTO 136.00% – News: Initiates development of free bingo app SIRC 105.88%– News: Reports record revenue for October, November 2016 BBLS 18.14% – News: Commences drilling program; Reports oil reserves 273% increase QEGY 14.94% – News: Issues shareholder update MRNA 14.80% – News: New Board of Directors member named CIIX 13.95% – News: Entered wholesale agreement with a CBD health brand, Enables retail of CBD products to target Asian health market DMPI 12.07% –…

WednesdayDec 14, 2016 2:04 pm

NetworkNewsBreaks – BrainStorm Cell Therapeutics (NASDAQ: BCLI) Trades Higher Following Positive Data from Phase 2 Study of NurOwn®

Shares of Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) are up 23% following the announcement that new, positive data from the company's phase 2 study of NurOwn® in ALS were presented by lead investigator Dr. James Berry at the 27th International Symposium on ALS/MND in Dublin, Ireland. The data showed disease symptoms were essentially halted for the period of the treatment effect. This effect was even more prominent in the pre-specified subgroup that was defined in order to exclude subjects whose disease was progressing slowly. "Importantly, there is evidence that NurOwn® may be halting disease progression or improving symptoms in some patients. The CSF biomarker profiles were…

WednesdayDec 14, 2016 2:00 pm

NetworkNewsBreaks – Advanced Environmental Petroleum Producers (AEPP) Obtains Technical Evaluation Agreement; Moves forward with Pilot Plant

Advanced Environmental Petroleum Producers (OTCQB: AEPP) this morning said it had received clearance to manufacture and install the full Pilot Plant from its exclusive technology supplier Pointsource Processing (PSP) for the extraction of gas and oil after receiving the acceptance of its Technical Evaluation Agreement (TEA) for Block 19 Certificate. "AEPP can now instruct Chapman Petroleum Engineers from Calgary Alberta Canada to proceed on site to complete the 51-101 Petroleum Reserve Report for Block 19," Nigel Bosworth, AEPP's chief technology officer, stated in the news release. To view the full press release, visit: http://nnw.fm/gTy1C About Advanced Environmental Petroleum Producers, Inc.…

WednesdayDec 14, 2016 1:58 pm

NetworkNewsBreaks – Vericel (NASDAQ: VCEL) Receives FDA Approval for MACI®; Shares Soar

Shares of Vericel Corp. (NASDAQ: VCEL) are up more than 60% mid-day after the company broke news of the approval of MACI® (autologous cultured chondrocytes on porcine collagen membrane) by the U.S. Food and Drug Administration (FDA) for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. MACI is the first FDA-approved cellularized scaffold product that applies tissue engineering processes to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. "We believe that the introduction of MACI, along with investments to expand our commercial organization…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks